drugset / Trial / NCT00113568

Safety Study of XP12B in Women With Menorrhagia

NCT00113568

Phase 3 Completed 784 enrolled Ferring Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.

Timeline

Start
2005-06
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1300 mg Oral

Indications